Source: European Medicines Agency (EU) Revision Year: 2026 Publisher: Dr. Falk Pharma GmbH, Leinenweberstr. 5, 79108 Freiburg, Germany, Tel.: +49 (0)761 1514-0, Fax: +49 (0)761 1514-321, E-mail: zentrale@drfalkpharma.de
Pharmacotherapeutic group: Antidiarrheals, intestinal anti-inflammatory/anti-infective agents, corticosteroids acting locally
ATC code: A07EA06
Budesonide is a non-halogenated glucocorticosteroid, which acts primarily anti-inflammatory via binding to the glucocorticoid receptor. In the treatment of EoE with this medicinal product, budesonide inhibits antigen-stimulated secretion of many pro-inflammatory signal molecules such as thymic stromal lymphopoietin, interleukin-13 and eotaxin-3 in the oesophageal epithelium, which results in a significant reduction of the oesophageal eosinophilic inflammatory infiltrate.
In a randomised, placebo-controlled, double-blind phase III clinical study (BUL-1/EEA) including 88 adult patients with active EoE (randomisation rate: 2:1), 1 mg budesonide given twice daily as an orodispersible tablet for 6 weeks induced clinico-pathologic remission (defined as both peak of <16 eosinophils/mm² high power field in esophageal biopsies and no or only minimal symptoms of dysphagia or pain during swallowing) in 34 out of 59 patients (57.6%) versus 0/29 patients (0%) in the placebo-group. Open-label extension of the treatment with 1 mg budesonide orodispersible tablet twice daily for further 6 weeks in patients without remission in the double-blind phase increased the rate of patients with clinico-pathologic remission to 84.7%.
In a randomised, placebo-controlled, double-blind phase III clinical study (BUL-2/EER) including 204 adult patients with EoE in clinico-pathological remission, patients were randomised to treatment with 0.5 mg budesonide twice daily (BID), 1 mg budesonide BID, or placebo (all given as orodispersible tablets) for 48 weeks. Primary endpoint was the rate of patients free of treatment failure with treatment failure defined as clinical relapse (severity of dysphagia or pain during swallowing of ≥4 points on a 0-10 nummerical rating scale, respectively), and/or histological relapse (peak of ≥48 eosinophils/mm² high power field), and/or food impaction requiring endoscopic intervention, and/or need of an endoscopic dilation, and/or premature withdrawal for any reason. Significantly more patients in the 0.5 mg BID (73.5%) group and the 1 mg BID (75.0%) group were free of treatment failure at week 48 compared to placebo (4.4%).
The most stringent secondary endpoint "deep disease remission", i.e., deep clinical, deep endoscopic and histological remission showed a clinically relevant higher efficacy in the 1 mg BID group (52.9%) compared to the 0.5 mg BID group (39.7%), indicating that a higher dose of budesonide is of advantage to achieve and maintain deep disease remission.
The double-blind period was followed by an optional 96-week open-label treatment with a recommended dose of 0.5 mg budesonide BID or up to 1 mg budesonide BID. More than 80% of the patients maintained clinical remission (defined as weekly Eosinophilic Esophagitis Activity Index-Pro ≤20) over the 96-week period, while only 2/166 patients (1.2%) experienced a food impaction. In addition, 40/49 patients (81.6%) maintained deep histological remission (0 eosinophils/mm² high power field in all biopsies) from baseline of study BUL-2/EER to the end of treatment of the 96-week open-label period. Over a period of up to 3 years (i.e., 96-week open-label treatment with budesonide orodispersible tablets, following a 48-week double-blind maintenance treatment) no loss of efficacy was observed.
A randomised, placebo-controlled, double-blind phase II/III clinical study BUU-5/EEA (PEDEOS-1) was conducted in 76 paediatric patients (2 to 17 years) with active EoE, comparing a 12-week oral treatment of two different daily doses of 0.2 mg/mL budesonide oral suspension versus placebo: 1) high dose (BOS-H; 2 to 11 years: 0.5 mg budesonide twice daily; 12 to 17 years: 1.0 mg budesonide twice daily); 2) low dose (BOS-L; 2 to 11 years: 0.5 mg budesonide once daily in the morning; 12 to 17 years: 1.0 mg budesonide once daily in the morning); 3) placebo suspension group.
The primary endpoint was the rate of patients with pathological remission (peak eos <16 eos/mm² hpf [i.e. <5 eos/mm² hpf]) and clinical response (≥30%) decrease in the total score of PEESS v2.0) at week 12. Significantly more patients in the BOS-H (69.2%) and BOS-L (46.2%) groups achieved the endpoint versus placebo (0.0%) (FAS-DB, p<0.0001). BOS-H induced histological remission in nearly all treated patients (88.5%) compared to BOS-L (61.5%) and to placebo (0%), independent of the localisation, extent, or severity of the oesophageal inflammation, as well as in both age subgroups. There was no signficant or clinically relevant difference in clinical response at week 12 (key secondary end-point). This is primarily explained by a high placebo response; however, the finding indicates that a reduction in symptoms may not reliably predict histological response.
The double-blind phase was followed by an optional 12-week open-label induction phase with BOS-H for patients not appropriately responding to BOS-H, BOS-L, or placebo during the double-blind phase. Following these additional 12 weeks of BOS-H induction treatment, 45 of 52 patients (86.5%) were brought into pathological remission associated with clinical response. Patients responding to induction therapy could receive an additional 24-week open-label therapy with BOS-L, with the option of escalation to BOS-H. In this phase, BOS was highly effective in maintaining and even further strengthening the clinical remission achieved during induction therapy. No results on histological remission are available as no endoscopies were conducted during the extension phase.
For information about the observed adverse reactions, see section 4.8.
Following administration of Jorveza 0.2 mg/mL oral suspension, budesonide is rapidly absorbed. Pharmacokinetic data after administration of a single dose of 1 mg budesonide to fasted healthy subjects in two different studies show a median lag time of 0.00 - 0.08 hours (range 0.00 - 0.17 hours) and a median time to peak plasma concentration of 0.7 - 1.00 hours (range 0.33 – 1.75 hours). The mean peak plasma concentration (Cmax) was 0.39 - 0.41 ng/mL (range 0.09 – 0.90 ng/mL) and the area under the plasma-concentration-time curve (AUC0-∞) was 1.47 - 1.49 hr*ng/mL (range 0.53 – 3.85 hr*ng/mL).
After administration of the oral suspension under fed conditions the Cmax of budesonide decreased by 36% - 41% while Tmax increased by 0.90 - 1.25 h when compared to the administration under fasting conditions. No effect of food intake was noted on AUC0-∞.
Following twice daily administration of 5 ml oral suspension over 7 days, budesonide showed an accumulation of approximately 15% for the extent of exposure (AUC0-24,ss), in comparison with the single dose.
In paediatric EoE patients (2 to 17 years) the bioavailability of budesonide from the oral suspension was shown to be approximately 60% lower than in adult healthy volunteers. Paediatric patients 2 to 5 years of age showed slightly higher median exposure parameters (AUC and Cmax) than the older age groups while the range of exposures in younger children was fully within the range of exposures simulated for other age groups.
In contrast, adult EoE patients treated with budesonide orodispersible tablets showed a 35% increase in peak plasma concentrations and a 60% increase in AUC0-12 compared to adult healthy subjects.
The apparent volume of distribution following oral administration of 1 mg budesonide to healthy adult subjects was 35.52 ± 14.94 L/kg and 42.46 ± 23.90 L/kg following administration of 4 mg budesonide to adult patients with EoE (PK data for budesonide orodispersible tablets). Plasma protein binding is on average 85 - 90%.
Metabolism of budesonide is decreased in adult EoE patients compared to healthy subjects resulting in increased plasma concentrations of budesonide.
Budesonide undergoes extensive biotransformation by CYP3A4 in the mucosa of the small intestine and in the liver to metabolites of low glucocorticosteroid activity. The glucocorticosteroid activity of the major metabolites, 6β-hydroxybudesonide and 16α-hydroxyprednisolone, is less than 1% of that of budesonide. CYP3A5 does not contribute significantly to the metabolism of budesonide.
The median elimination half-life in healthy subjects is 4.05 - 4.50 hours (range 2.38 - 5.47 hours). Budesonide is eliminated only in marginal if any amounts by the kidney. No budesonide, but only budesonide metabolites were detected in urine.
A relevant proportion of budesonide is metabolised in the liver by CYP3A4. The systemic exposure of budesonide is considerably increased in patients with severely impaired hepatic function. No studies have been conducted with Jorveza in patients with impaired liver function.
The effect of renal impairment on budesonide PK was not evaluated in a dedicated clinical study. Therefore budesonide is not recommended for use in patients with severe renal impairment.
Preclinical data in acute, subchronic and chronic toxicological studies with budesonide showed atrophies of the thymus gland and adrenal cortex and a reduction especially of lymphocytes.
Budesonide had no mutagenic effects in a number of in vitro and in vivo tests.
A slightly increased number of basophilic hepatic foci were observed in chronic rat studies with budesonide, and in carcinogenicity studies, an increased incidence of primary hepatocellular neoplasms, astrocytomas (in male rats) and mammary tumours (female rats) were observed. These tumours are probably due to the specific steroid receptor action, increased metabolic burden and anabolic effects on the liver, effects which are also known from other glucocorticosteroids in rat studies and therefore represent a class effect in this species.
Budesonide had no effect on fertility in rats. In pregnant animals, budesonide, like other glucocorticosteroids, has been shown to cause foetal death and abnormalities of foetal development (smaller litter size, intrauterine growth retardation of foetuses and skeletal abnormalities). Some glucocorticoids have been reported to produce cleft palate in animals. The clinical relevance of these findings to man has not been established (see section 4.6).
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.